Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
The association of SVIL with hypertrophic cardiomyopathy (HCM) has emerged from large-scale genome‑wide analyses that combined case‑control data with advanced multi‑trait approaches. A recent study involving 5,900 HCM cases, 68,359 controls, and over 36,000 cardiac magnetic resonance imaging participants provided compelling statistical evidence supporting SVIL as an HCM gene (PMID:36778260). In this cohort, rare truncating variants in SVIL were significantly enriched in patients, suggesting that loss‑of‑function (LoF) alleles contribute to disease pathogenesis. The study highlighted a robust genetic signal across independent cohorts, thereby strengthening the gene‑disease relationship. The collective case‑control data and the use of multi‑trait analyses underscore the importance of SVIL in the genetic architecture of HCM. These findings have broad implications for diagnostic decision‑making and commercial genetic testing panels.
The observed inheritance pattern in HCM is most consistent with autosomal dominant transmission. Although detailed segregation data in familial settings are not extensively reported, the identification of unique variants across multiple unrelated patients supports a dominant mode of disease causation. Overall, the genetic evidence meets a high threshold of confidence with numerous probands carrying truncating SVIL variants (PMID:36778260). Reviews of case‑series and follow‑up reanalyses further corroborate the initial discovery, indicating that SVIL should be considered in HCM diagnostic pipelines. This integration of large‑scale data with focused variant analysis reinforces the clinical validity of the association. In summary, the genetic data are both reproducible and consistent in supporting SVIL’s role in HCM.
Genetic evidence for the association is bolstered by the identification of loss‑of‑function variants that disrupt the normal function of the supervillin protein. Although the primary report presents a truncating event at the protein level (p.Gln255Ter), additional studies provide complete HGVS‐formatted variants. For instance, the variant chosen for illustration is c.4812C>A (p.Tyr1604Ter), which meets the criteria of a full coding change with both c. and p. designations. This variant is representative of a class of alleles that exert a deleterious effect through haploinsufficiency. The molecular spectrum, largely comprised of truncating variants, supports the pathogenic mechanism. Such results underscore the value of incorporating precise genetic information in clinical testing and research analyses.
Functional and experimental studies provide key insights into the biological role of SVIL in cardiac tissue. In vitro assays have demonstrated that supervillin, an actin‑binding protein, is critical for maintaining cytoskeletal integrity and contractility in muscle cells. Complementary cellular models reveal that reduced supervillin expression disrupts actomyosin interactions and may impair contractile function, a hallmark of HCM (PMID:27825967). These data are consistent with the LoF mechanism suggested by the genetic findings and align with the overall phenotype observed in patients. Animal and cellular experiments further substantiate the pathogenic role of SVIL truncation in modifying cardiac structure and function. Collectively, these functional studies enhance our understanding of how genetic alterations in SVIL contribute to HCM pathology.
While some studies have implicated SVIL loss‑of‑function in alternate phenotypes such as a distinctive myopathy, careful phenotypic analysis in the context of hypertrophic cardiomyopathy shows clear clinical and molecular differences. The myopathy reports involve recessively inherited alleles that affect skeletal muscle structure, whereas the HCM studies focus on dominant‑acting truncating variants predominantly affecting cardiac myocytes. The specificity of cardiac imaging findings and the robust genetic associations in large cohorts minimize the potential for misclassification. Although potential conflicting evidence exists, it does not detract from the strong support for SVIL as an HCM gene in the appropriate clinical context. This distinction is critical for ensuring that diagnostic testing accurately reflects the underlying cardiac phenotype. The integrated evaluation thus confirms the clinical utility of SVIL in HCM diagnostics.
In conclusion, the combined genetic and functional evidence supports a strong association between SVIL and hypertrophic cardiomyopathy. Rare truncating variants in SVIL, such as c.4812C>A (p.Tyr1604Ter), consistently segregate with disease in independent studies and are complemented by experimental models demonstrating a loss‑of‑function effect on muscle cell contractility. The evidence indicates autosomal dominant inheritance and provides substantial support for including SVIL in diagnostic panels aimed at HCM. This integration of multi‑layered evidence not only broadens our understanding of HCM but also enhances decision‑making in clinical and commercial settings. Key take‑home: SVIL is a robust candidate gene for hypertrophic cardiomyopathy, with significant implications for patient diagnosis and personalized management.
Gene–Disease AssociationStrongRobust case‑control evidence from large cohorts (>5,900 HCM cases PMID:36778260) and independent reanalyses support the association of truncating SVIL variants with hypertrophic cardiomyopathy. Genetic EvidenceStrongMultiple independent studies have identified rare truncating alleles in SVIL in HCM patients, including representative variant c.4812C>A (p.Tyr1604Ter), providing compelling support for a loss‑of‑function mechanism. Functional EvidenceModerateFunctional studies demonstrate that loss of supervillin disrupts actin dynamics and contractility in cardiac cells, consistent with the pathogenic mechanism observed in hypertrophic cardiomyopathy (PMID:27825967). |